Please login to the form below

Not currently logged in
Email:
Password:

Zalviso

This page shows the latest Zalviso news and features for those working in and with pharma, biotech and healthcare.

Grunenthal and AcelRx’s Zalviso approved in EU

Grunenthal and AcelRx’s Zalviso approved in EU

Grunenthal and AcelRx’ s Zalviso approved in EU. Provides new treatment for post-operative pain. ... delivery. AcelRx developed Zalviso and entered into a commercial collaboration with Grunenthal at the end of 2013.

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    It is our passion to help these patients.”. It is also investing in New Technical Entities (NTEs) which include new formulations and devices, acquiring Zalviso, a combination of a medical device

  • Pharma deals in September 2015 Pharma deals in September 2015

    PDL BioPharma is buying out the majority of the expected royalty stream from EU sales of AcelRX's phase III product, Zalviso for $65m. ... Royalty monetisation. 110. AcelRx Pharmaceuticals. PDL BioPharma. Zalviso sub-lingual formulation of sufentanil.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics